Gubra (GUBRA) R&D Day 2026 summary

Pipeline overview and program updates

• Four assets were in clinical development in 2026, including two partnered Phase 2 obesity programs; targets are 8–10 clinical-stage assets by 2030 and 1–2 proprietary candidate nominations annually from 2030.

• Since the 2023 IPO, the pipeline grew from one to four clinical-stage assets.

• GUB-UCN2 is the lead proprietary program, with obesity as the entry indication and potential expansion into age-related functional decline, sarcopenia, and cardiorenal disease, subject to clinical evidence.

• By 2030, ventures aim to contribute two to three clinical assets, with a broader target of two to three operating ventures.

Clinical trial data and development milestones

• Preclinical GUB-UCN2 studies showed fat-mass reduction with lean-mass preservation or increase, including in combinations with semaglutide, tirzepatide, and amylin or cagrilintide.

• GUB-UCN2 Phase 1/2a plans to enroll ~188 participants and assess safety, body composition, and function; SAD data are expected H1 2027, six-week MAD data Q4 2027/Q1 2028, and 16-week dosing data H1 2029.

• ABBV-295 Phase 1 showed up to ~10% weight reduction over 12–13 weeks; AbbVie’s ~360-participant Phase 2 has a week-32 primary endpoint and treatment through week 52.

• BI 3034701 advanced to Phase 2; the ~300-participant, 42-week study assesses dose response, with body-weight change at week 42 as the primary endpoint.

• Hemab initiated Phase 1 for a long-acting plasmin inhibitor; Amylyx is conducting IND-enabling work on a GLP-1 receptor antagonist, and Camurus is formulating a PTH analog.

R&D strategy and innovation priorities

• streaMLine combines AI-driven peptide design and data analysis with high-throughput screening and multi-parameter optimization; hit-to-candidate progression can take under 1.5 years.

• Platform priorities include long-acting and macrocyclic peptides, oral delivery, multi-agonism, peptide-peptide conjugates, automation, robotics, and AI.

• Therapeutic priorities span obesity and cardiovascular, renal, and metabolic disease; age-related functional decline; and immunology and inflammation.

• AI-supported 3D imaging covers whole-brain and muscle analysis, with CRO capacity to process data from more than 800 brains per month.